about
Omalizumab treatment in brittle asthma.Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbationThe role of endothelium-derived mediators in exercise-induced bronchoconstriction.Changes in high-sensitivity C-reactive protein in serum and exhaled breath condensate after intensive exercise in patients with allergic asthma.RANTES in exhaled breath condensate of allergic asthma patients with exercise-induced bronchoconstriction.The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease.Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients with mild allergic asthma.Changes in RANTES and β-Thromboglobulin after Intensive Exercise in Patients with Allergic AsthmaHigh-sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthmaN-acetyl-beta-hexosaminidase activity in asthmaEndothelin-1 in exhaled breath condensate of stable and unstable asthma patientsRANTES in exhaled breath condensate of stable and unstable asthma patientsEotaxin in exhaled breath condensate of allergic asthma patients with exercise-induced bronchoconstriction[Statins and asthma]Inflammatory markers and acid-base equilibrium in exhaled breath condensate of stable and unstable asthma patientsAnti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthmaRANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapyAirway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy
P50
Q37634330-F2A49E69-AB69-4E18-A305-BB680F0B24CEQ41880272-481DE35B-99BE-40A6-9B41-AACC3F35882CQ42170853-2514CF7A-9AF4-40FE-AE17-CDF6609CA9F5Q43112815-B0C443C6-82D8-45E0-A3E9-62F22C13C8E2Q43227195-D737016D-7F15-4911-8391-291987F6128AQ46530790-01AE2D7C-89B9-4F23-93B8-C95E854E41B2Q46916718-E6BFFC77-0EBA-441E-8A3E-94DA96C1A64FQ59843798-A4F65E3E-B2AD-44D2-B94A-8FC930E39427Q59843805-E273B1F5-6B12-4713-A6F3-FA8F018854FEQ80513095-2D991115-F5BE-458B-A767-5FC4FC7FEC3BQ81039080-2D9FA302-9274-482C-A622-06D8049383B5Q81585337-778AA37F-59EF-4ADC-8A16-94850C83C3ABQ83254157-0D74ACBC-DFA6-4247-8F6B-0F19807490B3Q83897802-29F9FF60-D124-43BA-855D-4EAB43BFF619Q84266578-19A8C39D-64DC-42C6-80CC-C8E03B5FD3A9Q84501314-2A8820B0-C486-468B-B0F3-C263A5F41CA7Q84600220-62011741-24B1-4290-B9AF-6EA3DCCB7C0FQ84974666-C2BAE9F2-8101-4107-820A-9819BC0B9685
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Ziemowit Zietkowski
@en
Ziemowit Zietkowski
@nl
type
label
Ziemowit Zietkowski
@en
Ziemowit Zietkowski
@nl
prefLabel
Ziemowit Zietkowski
@en
Ziemowit Zietkowski
@nl
P31
P496
0000-0003-2272-4870